STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...
Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GAITHERSBURG, Md., October ...
The main market opportunities lie in expanding Whole Genome Sequencing at birth, rapid growth in Direct to Consumer Testing, advancing sequencing technologies, and overcoming industry barriers.
SAN FRANCISCO, March 30, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced a major expansion of its genetic testing ...
Genetic testing leader GeneDx HoldingsGDX is Monday's pick for IBD 50 Growth Stocks To Watch. The medical services stock is climbing in a 7-week-long consolidation pattern as the company's earnings ...
Children who undergo expansive genetic sequencing may not be getting the thorough DNA analysis their parents were expecting, say experts at UT Southwestern Medical Center. A review of clinical tests ...
The Patient Access Program helps to ensure more equitable care across pediatric epilepsy populations. Exome testing is recommended as a first-line test for patients with unexplained epilepsy by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results